- The DehydraTECH formulation delivered measurable quantities of cannabidiol (“CBD”) into blood in as little as 2 minutes;
- Lexaria’s technology delivered more CBD to bloodstream in 15 minutes than conventional medium chain triglyceride (“MCT”) oil based control formulation achieved in 60 minutes;
- The area under the curve (“AUC”) for Lexaria’s patented DehydraTECH formulation was 389% more than the MCT oil control formulation;
- Lexaria’s DehydraTECH formulation delivers cannabinoids at industry-leading volumes and speed while effectively masking bitter flavor and aroma profiles.
KELOWNA, BC / ACCESSWIRE / May 15, 2019 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the “Company” or “Lexaria”), a drug delivery platform innovator, has proven in animal testing that Lexaria’s DehydraTECHTM technology delivers cannabinoids to the bloodstream much more quickly and effectively than conventional industry cannabinoid edible formulation designs that often combine cannabinoids with MCT oils such as